AS

Active Director Director DIN 07189548
DIN 07189548 First appointment Jun 2018 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jun 2018
Shareholding value •••• Premium profile

About Amit Sen

Data last updated:

Amit Sen is a Director at Glorior Biotech Private Limited (since 2018). The company operates in Pharma. Glorior Biotech Private Limited reported revenue of ₹3.76 Cr (FY 2024).

DIN 07189548
Primary Designation Director
Industry Pharma
First Appointment 01 Jun 2018
Oldest Company Age 11 yrs
Largest company Glorior Biotech Private Limited · ₹3.76 Cr (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Glorior Biotech Private Limited U74900WB2015PTC206678
Director01 Jun 20182015₹3.76 Cr (FY 2024)Active

Board colleagues of Amit Sen

Directorship timeline

Open interactive timeline →
Glorior Biotech Private Limited
Premium access

Shareholding and investment profile for Amit Sen

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Amit Sen

Amit Sen currently holds 1 directorship: Glorior Biotech Private Limited (Director, since 01 Jun 2018, revenue ₹3.76 Cr (FY 2024)).

Amit Sen was first appointed on 01 Jun 2018 as Director at Glorior Biotech Private Limited.

The current boards of Amit Sen's companies include Dharma Debnath (Glorior Biotech Private Limited), Shankha Ghosh (Glorior Biotech Private Limited), Sumanta Sadhukhan (Glorior Biotech Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available